Abbonarsi

Antenatal corticosteroid administration: understanding its use as an obstetric quality metric - 25/01/14

Doi : 10.1016/j.ajog.2013.09.024 
Suchitra Chandrasekaran, MD , Sindhu K. Srinivas, MD, MSCE
 Maternal and Child Health Research Program, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 

Reprints: Suchitra Chandrasekaran, MD, The Hospital of the University of Pennsylvania, 3400 Spruce St, 2000 Courtyard, Philadelphia, PA 19102.

Abstract

Objective

In 1994, the National Institutes of Health recommended a full course of antenatal corticosteroids (ACS) to women who were at risk of delivery at 24-32 weeks of gestation. In 2010, the Joint Commission on Accreditation of Healthcare Organization incorporated ACS administration rates as a perinatal core quality measure. The objective of this study is (1) to assess ACS administration rates among eligible patients at a tertiary care center and (2) to identify modifiable factors to optimize administration rates.

Study Design

A retrospective chart review of preterm deliveries at <37 weeks of gestation from July 2009 to July 2011 was performed. Hospital level data, delivery information, obstetric history, and neonatal outcomes were abstracted. Categoric variables were compared with the use of the χ2 test. Continuous variables were compared with the use of a 2-sample t-test, Wilcoxon rank-sum, or Kruskal Wallis tests.

Results

Nine hundred four women had preterm delivery; 38% of them delivered from 24-34 weeks of gestation. Of the eligible patients, 81.3% received at least 1 dose of ACS, and 69.6% received both doses before delivery. The median time from evaluation to ACS administration was 2.6 hours (interquartile range, 1.6–4.8 hours). Thirty-three percent of the patients who did not receive ACS had had a previous triage visit within 2 weeks of delivery (66.6% of them were evaluated for symptoms of preterm labor) vs 2.8% for those women who received ACS.

Conclusion

Of the eligible patients, 81.3% received at least 1 dose of ACS. Tangible opportunities that were identified for systems-based improvement in ACS administration rates included decreasing the time interval from patient evaluation to ACS administration and standardizing outpatient follow-up evaluation for patients who were discharged with symptoms of preterm labor.

Il testo completo di questo articolo è disponibile in PDF.

Key words : antenatal corticosteroid, neonatal outcome, quality metric


Mappa


 Supported by Reproductive Epidemiology Training, National Institutes of Health, grant number T32HD007440-16.
 The authors report no conflict of interest.
 Cite this article as: Chandrasekaran S, Srinivas SK. Antenatal corticosteroid administration: understanding its use as an obstetric quality metric. Am J Obstet Gynecol 2014;210:143.e1-7.


© 2014  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 210 - N° 2

P. 143.e1-143.e7 - febbraio 2014 Ritorno al numero
Articolo precedente Articolo precedente
  • Circulating angiogenic factors in monochorionic twin pregnancies complicated by twin-to-twin transfusion syndrome and selective intrauterine growth restriction
  • Yoav Yinon, Elad Ben Meir, Alexandra Berezowsky, Boaz Weisz, Eyal Schiff, Shali Mazaki-Tovi, Shlomo Lipitz
| Articolo seguente Articolo seguente
  • Paper gestational age wheels are generally inaccurate
  • Linda R. Chambliss, Steven L. Clark

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.